Identification of medium-sized copy number alterations in whole-genome sequencing

Cancer Informatics
Hatice Gulcin OzerKun Huang

Abstract

The genome-wide discoveries such as detection of copy number alterations (CNA) from high-throughput whole-genome sequencing data enabled new developments in personalized medicine. The CNAs have been reported to be associated with various diseases and cancers including acute myeloid leukemia. However, there are multiple challenges to the use of current CNA detection tools that lead to high false-positive rates and thus impede widespread use of such tools in cancer research. In this paper, we discuss these issues and propose possible solutions. First, since the entire genome cannot be mapped due to some regions lacking sequence uniqueness, current methods cannot be appropriately adjusted to handle these regions in the analyses. Thus, detection of medium-sized CNAs is also being directly affected by these mappability problems. The requirement for matching control samples is also an important limitation because acquiring matching controls might not be possible or might not be cost efficient. Here we present an approach that addresses these issues and detects medium-sized CNAs in cancer genomes by (1) masking unmappable regions during the initial CNA detection phase, (2) using pool of a few normal samples as control, and (3) employi...Continue Reading

References

Oct 12, 2004·Biostatistics·Adam B OlshenMichael Wigler
May 5, 2005·Journal of the National Cancer Institute·Federico CappuzzoMarileila Varella-Garcia
Nov 24, 2006·Nature·Richard RedonMatthew E Hurles
Oct 17, 2008·Nature·Edwin H Cook, Stephen W Scherer
Mar 6, 2009·Genome Biology·Ben LangmeadSteven L Salzberg
May 20, 2009·Bioinformatics·Heng Li, Richard Durbin
Jun 6, 2009·Bioinformatics·Ruiqiang LiJun Wang
Jan 12, 2010·Annual Review of Medicine·Paweł Stankiewicz, James R Lupski
Jan 30, 2010·Bioinformatics·Aaron R Quinlan, Ira M Hall
Feb 10, 2011·PloS One·Christopher A MillerAleksandar Milosavljevic
Aug 11, 2011·Bioinformatics·Jarupon Fah SathirapongsasutiStanley F Nelson
Nov 9, 2011·Proceedings of the National Academy of Sciences of the United States of America·Ruibin XiPeter J Park
Jan 26, 2012·PloS One·Thomas DerrienPaolo Ribeca
Apr 4, 2012·Expert Review of Molecular Diagnostics·Meagan A Jacoby, Matthew J Walter
Mar 28, 2013·Genome Biology·Markus MayrhoferAnders Isaksson

❮ Previous
Next ❯

Software Mentioned

GEnome Multitool
ReadDepth
SOAP2
Integrated Genomic Viewer
VarScan2
R DNAcopy library
HMMCopy
SegSeq
- FREEC
RepeatMasker

Related Concepts

Related Feeds

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.